Enliven Therapeutics ELVN Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's operating lease right-of-use assets in other assets?
- Enliven Therapeutics (ELVN) reported operating lease right-of-use assets in other assets of $290K in Q1 2026.
- How has Enliven Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- Enliven Therapeutics's operating lease right-of-use assets in other assets decreased by 58.6% year-over-year, from $700K to $290K.
- What is the long-term trend for Enliven Therapeutics's operating lease right-of-use assets in other assets?
- Over 4 years (2021 to 2025), Enliven Therapeutics's operating lease right-of-use assets in other assets has grown at a -7.6% compound annual growth rate (CAGR), from $525K to $383K.